By Christian Moess Laursen
Argent BioPharma said it plans to leave the London Stock Exchange while mulling a listing in the U.S.
The pharmaceutical company, which will keep its stock-market listing in Australia, said it has taken steps to cancel the admission of its shares on the LSE.
The decision followed a review of both the listing requirements and costs associated with the transfer of all its ordinary shares, it said Friday.
Argent Biopharma expects the last day of trading on the LSE to be Dec. 31.
The company said it might still look to explore opportunities to expand its accessibility to investors, including a potential listing on an U.S. exchange.
The company's main operations and management are based in the EU, with a growing investor base in the U.S.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
November 29, 2024 02:57 ET (07:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。